PA-TU-8902

PA-TU-8902 is a human pancreatic ductal adenocarcinoma (PDAC) cell line, established in 1985 from a primary grade II tumor of a 44-year-old female. Its paramount scientific advantage lies in its genuinely metastatic phenotype: unlike most PDAC lines that fail to colonize distant organs in vivo, PA-TU-8902 consistently forms lung, esophageal, and pleural metastases upon intravenous injection in nude mice, faithfully recapitulating late-stage human disease.

Genetically, the line harbors endogenous KRAS and TP53 mutations-the two cardinal drivers of human PDAC-while remaining negative for EBV, HBV, HCV, HIV, and HTLV, ensuring biosafety for in vivo experimentation. Its well-characterized pseudotetraploid karyotype, authenticated STR profile, and documented secretion of urokinase, cathepsins B/D, and cytokines (e.g., EpCAM+) position it as a mechanistically tractable platform for studying protease-driven invasion, cancer cachexia, and tumor-stroma crosstalk.

Furthermore, PA-TU-8902 exhibits exceptional amenability to genetic engineering. It has been successfully deployed for CRISPR/Cas9-mediated SMAD4 knockout to dissect TGF-β signaling and mitophagy-driven chemoresistance, and engineered to stably co-express GFP, luciferase, and chicken ovalbumin (OVAL) for in vivo imaging and immunotherapy modeling. With a manageable doubling time (25-40 h) and negative mycoplasma status, PA-TU-8902 remains a reference standard for translational PDAC research spanning metastasis biology, drug resistance, and preclinical therapeutic screening.